



We're tackling big challenges in healthcare


Oncology

\$201B (2021) | 9.7% CAGR

1 out of 6 people worldwide dies due to cancer.

Neurodegenerative \$34B (2020) | 4.9% CAGR

1 out of 9 people worldwide dies due to a disorder of the nervous system.



Only 1 out of 50 people worldwide lives to reach the age of 80.


Inflammatory diseases

\$98B (2020) | 9.3% CAGR

3 out of 5 people worldwide die due to chronic inflammatory diseases.



The market demands a more effective solution





We are scientist-founders



SAMANTHA DALE STRASSER, PHD CSO & Co-founder | PhD, MIT

- Developed Pepper's technology
- Studied multi-omics while an NSF Graduate Research Fellow in EECS mentored by Douglas A. Lauffenburger at MIT
- Former Churchill Scholar and Goldwater Scholar









Beth Israel Lahey Health

Beth Israel Deaconess Medical Center



CHRISTOPHER NICHOLSON, PHD

Head, Biology | PhD, Newcastle University

- Identified novel regulators of vascular calcification and atherosclerosis as a Senior Research Fellow at Harvard Medical School and MGH
- Lead development of COVID-19 outcome prediction model













JON HU

CEO & Co-founder | MBA, Harvard Business School

- Led Atidiv (formerly Loft), an enterprise solutions Guild portfolio company, as its CEO, growing the company from 200 to 300 people
- Expanded Techweek, a tech conference and Guild portfolio company, to 2 new cities as COO







Guild Capital

Shire

^atidiv

techweel:



Head, BD | PhD, Brown University

- Pharma equity analyst at Cowen
- Built strong network of relationships as she led academic projects in Ferroptosis resistance and studied ovarian cancer and reproductive systems, resulting in 9 publications while at Brown University and UMass Med School





COWEN







Our advisory board



Stanford University







/\ Variant Bio



GNS HEALTHCARE











DOUGLAS LAUFFENBURGER, PHD

- Professor, MIT
- Founder, Biological Engineering, MIT



DEAN FELSHER, MD, PHD

- Professor, Oncology, Stanford
- Director, Translational Research, Stanford



IMRAN NASRULLAH, JD

- VP & Head, Open Innovation Center North America – East, Bayer
- Former Director, Strategic Partnering & Business Development
 & Licensing, Boehringer-Ingelheim



JEROME WINDSOR, PHARMD

- SVP, Corporate Development & Product Strategy, GNS Healthcare
- Former VP, Strategy & Business
 Development, Median Technologies



TOM RUSH, PHD

- Chief R&D Officer, Variant Bio
- Former US Lead, Functional Genomics, GlaxoSmithKline




PETER HORNBECK, PHD

- Director, Cell Signaling Technology
- Founder, PhosphoSitePlus



Full-stack omics solutions are inevitable


Pepper is leading the way forward



Farther




Transomics ushers in a new era of drug discovery





Pepper's PROSPER platform

A full-stack solution advancing drug discovery from target ID through clinical trials





EXPANDING TREATMENT CAPABILITIES



Our business model

Platform partnerships

- Partner with drug developers
- Upfront and milestone payments

Internal pipeline

- Develop the highest priority targets and assets
- Drug discovery from beginning to end
- License / sell to drug developers after de-risking



We are building the world's largest proprietary transomics database

Pepper-led (de novo)

- Funded by Pepper
- Supports platform advancement, validation, and benchmarking

Partnerships

- Pepper owns or has exclusive, perpetual raw data access
- Pepper owns all internally processed data

SOURCES

- Drug developers
- Academic labs
- Strategic partners

Publicly available

- Cleaned, formatted, and integrated
- Proprietary algorithm used



Demonstrated PoC across three therapeutic areas

Neurodegenerative

Working with a paid partner



Proprietary disease database

Transomic neuro disease data



Drug MOA study Indication expansion



Pending paper Strasser et al., 2022

Oncology

Developing proprietary database and publishing under Pepper Bio




Proprietary disease database

Transomic oncology disease data



Cell SystemsBrubaker, et al., 2019




Cancer Discovery Poulin, et al., 2019

Inflammatory

Pre-clinical validation with industry partner



Indication expansionExpansion into IBD from RA



Integrative
Biology
Strasser, et al., 2019



Science Signaling Lyons, et al., 2018



Our assets

industry and academic partnerships

partnership letters of intent

peer-reviewed publications and patents

team members



Raising \$6M; \$2M committed


		2022	2	2023
ONC - NOVEL TARGETS	\$0.9M			
For licensing and/or internal pipeline				
ONC - TARGET ID AND INDICATION EXPANSION	\$1.1M			
Enhance target ID and automate indication expansion capab	ilities			
ONC – TOXICITY PREDICTION	\$1.1M			
Develop toxicity prediction capabilities				
NEURO – TARGET ID AND INDICATION EXPANSION	\$1.8M			
Enhance target ID and automate indication expansion capab	ilities			
INDUSTRY AND ACADEMIC VALIDATION	\$1.0M			Series
Initiate 5 additional academic and industry partnerships with	milestone p	ayments		



Join us and deliver real impact in healthcare

Oncology Neurodegenerative \$201B (2021) | 9.7% CAGR Inflammatory diseases \$34B (2020) | 4.9% CAGR \$98B (2020) | 9.3% CAGR 1 out of 6 people worldwide 1 out of 9 people worldwide dies due to cancer. 3 out of 5 people worldwide dies due to a disorder of the nervous system. die due to chronic inflammatory diseases. Only 1 out of 50 people worldwide lives to reach the age of 80.

Pepper Bio is working toward helping more patients live longer, fuller lives.





Take part in advancing the future of drug discovery.

CONNECT WITH PEPPER BIO

jonhu@pepper.bio | www.pepper.bio